In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The closing price of Seres Therapeutics Inc (NASDAQ: MCRB) was $16.87 for the day, down -0.30% from the previous closing price of $16.92. In other words, the price has decreased by -$0.30 from its previous closing price. On the day, 0.13 million shares were traded. MCRB stock price reached its highest trading level at $17.27 during the session, while it also had its lowest trading level at $16.51.
Ratios:
Our analysis of MCRB’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.30 and its Current Ratio is at 2.30. In the meantime, Its Debt-to-Equity ratio is 1.95 whereas as Long-Term Debt/Eq ratio is at 1.72.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 15 ’25 when Young Teresa L. sold 1,042 shares for $17.30 per share. The transaction valued at 18,027 led to the insider holds 8,401 shares of the business.
Shaff Eric D. sold 217 shares of MCRB for $3,754 on Nov 15 ’25. The Director now owns 11,113 shares after completing the transaction at $17.30 per share. On Nov 15 ’25, another insider, DesRosier Thomas, who serves as the insider of the company, sold 76 shares for $17.30 each. As a result, the insider received 1,315 and left with 7,623 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MCRB now has a Market Capitalization of 152614784 and an Enterprise Value of 190229776. As of this moment, Seres’s Price-to-Earnings (P/E) ratio for their current fiscal year is 27.79. For the stock, the TTM Price-to-Sale (P/S) ratio is 436.05 while its Price-to-Book (P/B) ratio in mrq is 3.38. Its current Enterprise Value per Revenue stands at 541.965 whereas that against EBITDA is -1.918.
Stock Price History:
The Beta on a monthly basis for MCRB is 0.19, which has changed by -0.13673466 over the last 52 weeks, in comparison to a change of 0.12159383 over the same period for the S&P500. Over the past 52 weeks, MCRB has reached a high of $29.98, while it has fallen to a 52-week low of $6.53. The 50-Day Moving Average of the stock is -7.33%, while the 200-Day Moving Average is calculated to be 20.18%.
Shares Statistics:
MCRB traded an average of 220.66K shares per day over the past three months and 551400 shares per day over the past ten days. A total of 8.76M shares are outstanding, with a floating share count of 6.63M. Insiders hold about 26.73% of the company’s shares, while institutions hold 10.72% stake in the company. Shares short for MCRB as of 1763078400 were 925479 with a Short Ratio of 4.19, compared to 1760486400 on 798666. Therefore, it implies a Short% of Shares Outstanding of 925479 and a Short% of Float of 16.299999.
Earnings Estimates
The stock of Seres Therapeutics Inc (MCRB) is currently in the spotlight, with 1.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$2.0, with high estimates of -$1.75 and low estimates of -$2.24.
Analysts are recommending an EPS of between $0.77 and $0.77 for the fiscal current year, implying an average EPS of $0.77. EPS for the following year is -$10.43, with 1.0 analysts recommending between -$10.43 and -$10.43.
